Internet Support Group for Parents of a Child With Neurofibromatosis Type 1

Learn more about:
Related Clinical Trial
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Mechanism of Action of Transcranial Direct Current Stimulation in Neurofibromatosis Type 1 Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial Pilot Randomized Control Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Open Trial of Telehealth Group for Improving Peer Relationships (PEERS) in NF1 Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1 A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Medical Treatment of “High-Risk” Neurofibromas Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Treatment of NF1-related Plexiform Neurofibroma With Trametinib Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Study of Sutent®/Sunitinib (SU11248) in Subjects With NF-1 Plexiform Neurofibromas Neurofibromatosis Type 1 Brain Tumor Genetic Risk Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I Reliability of Functional Outcome Measures in Neurofibromatosis 1 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach. Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST) Quality of Friendships in Children With Neurofibromatosis Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Interventions for Reading Disabilities in NF1 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain Neurobiology and Treatment of Reading Disability in NF-1 From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms MicroRNAs in Patients With Neurofibromatosis Type 1 Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas Stem Cells in NF1 Patients With Tumors of the Central Nervous System Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 Reading Disability in Children With NF1 Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients Functional Imaging and Reading Deficit in Children With NF1 Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 Effect of Lamotrigine on Cognition in NF1 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia Non-invasive Stimulation in Neurofibromatosis Type 1 Modifying Genes in Neurofibromatosis 1 Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) Neurofibromatosis Type 1 Patient Registry Frameshift Peptides of Children With NF1 Prevalence of Constitutional Mismatch-repair Deficiency Among Suspected Neurofibromatosis Type 1/Legius Syndrome Children Without a Malignancy and Without a NF1 or SPRED1 Mutation How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem

Brief Title

Internet Support Group for Parents of a Child With Neurofibromatosis Type 1

Official Title

Effects of an Internet Support Group for Parents of a Child With Neurofibromatosis Type 1

Brief Summary

      Background:

      - Studies show that Internet Support Groups (ISGs) can help parents of children with chronic
      conditions. Researchers want to find out if ISGs can help parents of a child with the genetic
      disorder Neurofibromatosis Type 1 (NF1).

      Objective:

      - To see if an ISG for parents with a child with NF1 can give the parents more social support
      and less anxiety.

      Eligibility:

      - Adults age 18 and older with a child (age 0 25 years) with NF1.

      Design:

        -  Participants will register for the study on a website hosted by the Children s Tumor
           Foundation.

        -  Participants will complete 5 questionnaires. These will be about their emotional
           well-being, their child s health status, and their contact information.

        -  The ISG will include a Discussion Forum that participants can enter 24 hours a day, 7
           days a week. A professional moderator will post questions and discussion topics. The
           moderator can also respond to questions. They will be a psychologist, a psychology
           associate, or a nurse-practitioner. Each one will be highly experienced at working with
           young people with NF1 and their families.

        -  The ISG also will contain a chat room. Here participants can chat with other users in
           real time. The chat room will be open for one 90-minute session per week.

        -  The ISG will remain open for 8 weeks. Then participants will retake 4 of the
           questionnaires from the beginning of the study. They will also complete 1 other
           questionnaire about their experiences with the ISG. Information from any messages
           participants post on the ISG website will be collected.

        -  Three months after the ISG closes, participants will complete the questionnaires one
           final time.
    

Detailed Description

      BACKGROUND:

        -  The complex symptom profile in NF1 puts children and adolescents with this condition at
           risk for a variety of physical, cognitive, and social-emotional difficulties. Thus,
           caring for a child with a chronic medical condition such as NF1 can be challenging.

        -  Over the last two decades, researchers have been examining the use of internet support
           groups (ISGs) as a means of connecting individuals with similar conditions, diagnoses,
           or challenges to provide emotional and informational support.

        -  While the benefits of ISGs have been well documented in many studies of medical
           patients, very few have examined the use of ISGs in parents of children with chronic
           medical conditions. Further, no studies have been conducted on an ISG in parents of a
           child with NF1.

      OBJECTIVES:

        -  The primary objective of this pilot study is to assess the effectiveness of an ISG
           designed for parents of children with NF1 on a measure of perceived social support.

        -  Secondary objectives are to assess effects of the ISG on self-efficacy, depression, and
           anxiety, and to explore themes and topics discussed in the ISG.

      ELIGIBILITY:

      Eligible participants must self-report:

        -  Being greater than or equal to 18 years of age

        -  Having a child with a diagnosis of NF1 between 0 and 25 years of age

        -  Living in the same home as the child with NF1

             -  Having regular access to a computer with internet capability

      DESIGN:

        -  Parents of children with NF1 will be recruited through Dr. Widemann s NF1 patient
           database and through the Children s Tumor Foundation s (CTF) NF registry.

        -  Eligible participants will be emailed a link to access the study website through the CTF
           website. Due to the nature of the study, consent will be obtained online.

        -  After consenting, participants will be administered (electronically) baseline measures
           of perceived social support, self-efficacy, depression, and anxiety. After 8 weeks,
           participants will complete the measures again via the same website, as well as a
           post-study questionnaire assessing their experiences with participation. Measures will
           be repeated at 3-months post-intervention.

        -  Content analyses will be performed to identify themes and needs of the participants
    


Study Type

Observational


Primary Outcome

ISG effects on perceived support

Secondary Outcome

 ISG effects on depression and anxiety

Condition

Neurofibromatosis 1


Study Arms / Comparison Groups

 Volunteers
Description:  Parents of children with NF1

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

33

Start Date

May 31, 2014

Completion Date

January 29, 2019

Primary Completion Date

April 6, 2015

Eligibility Criteria

        -  ELIGIBILITY CRITERIA

        INCLUSION CRITERIA FOR PARENT PARTICPANT:

        Participants must self-report being the primary caregiver of one or more children ages 0 to
        25 with a confirmed diagnosis of NF1.

        Participants must report being at least 18 years of age.

        Participants must report living in the same home as the child(ren) with NF1 a majority of
        the time.

        Participants must report having regular access to a computer and internet connection.

        Participants will indicate they do not have any plans to start any other internet support
        group for parents of children with NF during the study time period.

        Participants must have the ability to read and communicate in the English language.

        Participants must have the ability to understand and the willingness to provide an online
        informed consent document.

        EXCLUSION CRITERIA FOR PARENT PARTICIPANT:

        Although individuals will be allowed to participate if they currently are part of another
        internet forum for NF, they will be excluded if they report they plan to start a new
        internet support group during the study period.
      

Gender

All

Ages

18 Years - 99 Years

Accepts Healthy Volunteers

No

Contacts

Staci M Peron, Ph.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT02153931

Organization ID

140113

Secondary IDs

14-C-0113

Responsible Party

Sponsor

Study Sponsor

National Cancer Institute (NCI)


Study Sponsor

Staci M Peron, Ph.D., Principal Investigator, National Cancer Institute (NCI)


Verification Date

January 29, 2019